TITLE

Vision and Purpose

PUB. DATE
February 2010
SOURCE
Pharmaceutical Representative;Feb2010, Vol. 40 Issue 2, p32
SOURCE TYPE
Periodical
DOC. TYPE
Interview
ABSTRACT
An interview with Chip Moore, veteran manager from Novo Nordisk Inc., is presented. When asked about the common traits of pharmaceutical representatives, he answers that all representatives he knows are optimists. He notes that representatives who have plans and visions are more accomplished representatives. He cites that the best representatives are the ones that can let physicians know what they are requesting.
ACCESSION #
47994309

 

Related Articles

  • Mylan shares down on Q2 miss. Investor's Business Daily // Investors Business Daily;8/ 8/2014, pA02 

    Shares of the generic drugmaker fell after a 1% EPS rise to 69 cents that missed by a penny and an 8% revenue increase to $1.84 bil that also fell short.

  • New Digs for Novo.  // Site Selection;Sep/Oct2011, Vol. 56 Issue 5, p683 

    The article focuses on the office building redevelopment project for the new U.S. headquarters of the medical firm Novo Nordisk Inc.

  • UC-Davis banning free sampes from pharma.  // Medical Ethics Advisor;Feb2007, Vol. 23 Issue 2, p21 

    The article reports on the decision of Sacramento, California-based University of California-Davis Health System to approve policies aimed at reducing pharmaceutical company's influence on physicians and other health care staff. The system will ban employees from accepting free drug samples,...

  • A textbook case of low esteem. Farrell, Liam // GP: General Practitioner;9/22/2003, p25 

    A recent themed edition of the BMJ examined the question of the extent to which doctors are influenced by pharmaceutical companies. The glossier the pharmaceutical packaging, the less likely a letter is to be worth opening. A cheap tattered envelope with a crudely scrawled address is most likely...

  • Epidemic Calls for Efforts That Extend Beyond Rx Treatment.  // Chain Drug Review;11/19/2012, Vol. 34 Issue 20, p58 

    The article presents views of Michael LaMotta, associate director of trade operations, strategic business operations at Novo Nordisk Inc. regarding the efforts of the company to combat with health care crisis concerning diabetes.

  • PRANDIMET 1mg/500mg.  // Physician Assistants' Prescribing Reference;Summer2009, Vol. 16 Issue 2, pA13 

    The article evaluates the antidiabetic tablets, Prandimet from the company Novo Nordisk & Sciele.

  • Once-daily injection to treat type 2 diabetes.  // Clinical Advisor;Apr2010, Vol. 13 Issue 4, p13 

    The article evaluates the antidiabetic drug Victoza from Novo Nordisk Inc.

  • BEST PLACES TO WORK IN N.J. MACK, DANIELLE // njbiz;12/30/2013, Vol. 25 Issue 51, p48 

    A list of best employers in New Jersey ranked by workplace quality is presented which includes Patton Boggs LLP, Novo Nordisk Inc., and WithumSmith + Brown PC.

  • Novo Nordisk Type 2 Diabetes Drug Cleared.  // Chain Drug Review;12/12/2016, Vol. 38 Issue 19, p71 

    The article mentions various drugs and treatments approved by food and Drug Administration includes drug Xultophy from Novo Nordisk for type 2 diabetes, clinical trials testing for the treatment of head and neck cancer from AstraZeneca PLC, and vaccine FluLaval Quadrivalent from GlaxoSmithKline PLC

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics